Navigation Links
Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
Date:3/4/2008

IBS-A) -- and 30% to 40% of these patients suffer from IBS-C. There are currently few available therapies to treat the nine million U.S. patients diagnosed with IBS-C.

About Linaclotide

Linaclotide is a first-in-class compound currently being tested for the treatment of IBS-C, CC, and other gastrointestinal disorders. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. In preclinical testing linaclotide was shown to increase fluid secretion into the intestine, accelerate intestinal transit, and decrease visceral pain. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. In Phase 2a trials, linaclotide improved bowel function as measured by both CSBMs and SBMs in patients with CC and IBS- C. An issued composition of matter patent for linaclotide provides protection to 2025. In September 2007, Microbia and Forest entered into a 50/50 collaboration to co-develop and co-promote linaclotide in United States.

About Microbia

Microbia (http://www.microbia.com) is an entrepreneurial pharmaceutical company dedicated to the science and art of great drugmaking. The Company is advancing several clinical candidates-linaclotide for the treatment of chronic constipation, irritable bowel syndrome with constipation, and other functional gastrointestinal disorders; and novel, next-generation cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Microbia also has a growing pipeline of additional drug candidates in earlier stages of development. Microbia Precision Engineering, Inc., a majority-owned subsidiary of Microbia, Inc., is an industrial biotechnology company developing and commercializing novel bioprocesses for the production of specialty chemicals. Microbia has raised $231 million in private equity financing and is located in Cambridge, Massachusetts.

About Forest Laboratories
'/>"/>

SOURCE Microbia, Inc. and Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
2. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. D1 Sports Training Facilities Adopt TurfAide(TM) Antimicrobial to New Synthetic Turf Fields from AstroTurf(R)
4. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
9. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
10. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... June 9 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced new ... mellitus program at,the American Diabetes Association,s 68th ... company,s proprietary recombinant human,hyaluronidase enzyme (rHuPH20) with ...
... Pivotal Study Highlighted at Recent Arizona Alzheimer,s ... Consortium Annual Conference in Phoenix -, PHOENIX and ... Health Research Institute today announced that they are,actively enrolling patients ... treatment of Alzheimer,s disease. The study will,evaluate the safety and ...
Cached Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 2Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 3
(Date:9/1/2015)... , ... September 01, 2015 , ... Routines… every family ... routines can help make things easier for parents, caregivers and children too. Here are ... transitions both big and small become more fluid. When a routine is implemented into ...
(Date:9/1/2015)... ... September 01, 2015 , ... Specialty Technical ... updated International Audit Protocol Consortium (IAPC) EHS audit protocol for the European Union. ... scope of their EHS regulatory obligations and rapidly collect, share, archive, and export ...
(Date:8/31/2015)... , ... September 01, 2015 , ... The PT Outcomes ... clinically relevant measures for physical therapy patients. The Registry is being developed by the ... Inc. stated "We are happy to be selected to contribute FOTO Outcomes measures as ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... in giving potential patients the resources they need to have a successful cosmetic ... board certified plastic surgeons; Cosmetic Town Journal is always ready to help. , ...
(Date:8/31/2015)... ... ... comes to undergoing a hair transplant, most patients have donor hair moved from one part ... hair on top of the scalp, as well as filling in areas missing hair, is ... other areas of their head. , What about patients who have a limited, or even ...
Breaking Medicine News(10 mins):Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2
... 2011 -- The portion of the brain responsible for visual ... study by researchers from the Hebrew University of Jerusalem and ... they read words in Braille show activity in precisely the ... readers read. The findings challenge the textbook notion that the ...
... & Infants Hospital of Rhode Island has been named ... Clinical Sciences Institute of OptumHealth, an independent audit company. ... are created equal. For complex medical conditions, the ... process, OptumHealth developed Centers of Excellence networks that provide ...
... D.C., 22 February 2011 Adolescence can herald the ... long-term consequences including developmental and social impairment. Research that ... can shine a bright light on the persistent disparities ... the fact that equitable mental health care across all ...
... MONDAY, Feb. 21 (HealthDay News) -- The experience of ... lives of women than men, a new study suggests. ... additional care, including follow-up and possibly counseling to optimally cope ... of the department of dermatology at Erasmus MC in ...
... BROOK, Ill. Radiologists who interpret a high volume of ... determining which suspicious lesions are not malignant, according to a ... of Radiology . "Contrary to our expectations, we ... study,s lead author, Diana S.M. Buist, Ph.D., M.P.H., senior investigator ...
... to experience more health-related quality of life issues than men ... skin cancer melanoma, according to a report in the February ... JAMA/Archives journals. "Although the prognosis is relatively good for ... risk for disease progression and have an increased risk of ...
Cached Medicine News:Health News:Brain doesn't need vision at all in order to 'read' material 2Health News:Brain doesn't need vision at all in order to 'read' material 3Health News:Women & Infants named Center of Excellence for Neonatal Care for fifth year 2Health News:Racial and ethnic minority adolescents less likely to receive treatment for major depression 2Health News:Surviving Melanoma May Take Different Toll on Women, Men 2Health News:Surviving Melanoma May Take Different Toll on Women, Men 3Health News:Higher volume reduces false positives in screening mammography 2Health News:Influence of skin cancer on quality of life appears more substantial for women 2